Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis.

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Psoriatic arthritis remains a common cause of morbidity in patients with psoriasis. Little is known about the natural history of the disease and dermatologists do not consistently screen for its presence. We describe a patient with severe psoriasis where long-term biologic therapy with a tumour necrosis factor inhibitor was interrupted for clinical reasons, leading to a rapidly evolving axial spondyloarthritis and oligoarthritis. This unusual presentation of psoriatic arthritis may reflect masking of the disease by long-term treatment with a tumour necrosis factor inhibitor. We advocate the use of screening for psoriatic arthritis, including before and during treatment with biologic therapies. © 2014 Informa Healthcare USA on behalf of Informa UK Ltd.
    Original languageEnglish
    Pages (from-to)61-62
    Number of pages1
    JournalJournal of Dermatological Treatment
    Volume25
    Issue number1
    DOIs
    Publication statusPublished - 2012

    Keywords

    • Biologic therapy
    • Psoriasis
    • Psoriatic arthritis
    • Tumour necrosis factor inhibitor
    • Ustekinumab

    Fingerprint

    Dive into the research topics of 'Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis.'. Together they form a unique fingerprint.

    Cite this